Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Erdafitinib in Healthy Subjects
NCT02218073Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erdafitinib in urothelial carcinoma (UC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve and 1 more. Started Oct 2014; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02218073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218073.